Prudential plc (PRU): Is Now the Time to Buy It?

Page 1 of 2

Prudential LOGOLONDON — I’m always searching for shares that can help ordinary investors like you make money from the stock market.

So right now I am trawling through the FTSE 100 and giving my verdict on every member of the blue-chip index. Simply put, I’m hoping to pinpoint the very best buying opportunities in today’s uncertain market.

Today, I am looking at Prudential plc (LON:PRU) to determine whether you should consider buying the shares at 1,097p.

I am assessing each company on several ratios:

Price-to-earnings (P/E): Does the share look good value when compared against its competitors?

Price Earnings Growth (PEG): Does the share look good value factoring in predicted growth?

Yield: Does the share provide a solid income for investors?

Dividend cover: Is the dividend sustainable?

So let’s look at the numbers:

Stock Price 3-yr EPS growth Projected P/E PEG Yield 3-yr dividend growth Dividend cover
Prudential 1,097p 60% 12.3 1 2.8% 22% 3

The consensus analyst estimate for this year’s earnings per share is 89p (11% growth) and dividend per share is 31p (4% growth).

Trading on a projected P/E of 12.3, Prudential plc (LON:PRU) is slightly cheaper than its peers in the life insurance sector, which are currently trading on an average P/E of around 13.2.

Prudential’s P/E and double-digit growth rate give a PEG ratio of around 1, which implies the share is fairly priced for the near-term earnings growth the firm is expected to produce.

Offering a 2.8% yield, Prudential plc (LON:PRU)’s dividend yield is below the life insurance sector average of 4%. In addition, Prudential has a three-year compounded dividend growth rate of only 22%, implying the yield will continue to underperform that of its peers.

However, the dividend is more than three times covered by earnings, giving Prudential plenty of room for further payout growth.

So, is now the time to buy Prudential?
Shares in life insurance provider Prudential have been going from strength to strength over the last year, rising nearly 50% compared to the FTSE 100 as a whole, which only gained 13% over the same period.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!